Top 20 neurology products by U.S. revenue 2016

This statistic displays the projected top 20 products for neurology diseases based on revenue in the United States during 2016. In that year, Abilify, an Otsuka product, is expected to generate approximately 322 million U.S. dollars in revenues, a decrease of some 1.7 billion dollars compared to 2014, caused by patent loss.

Top 20 neurology products in the U.S. based on revenue in 2016 (in million U.S. dollars)*

Product name (company)	Revenue in million U.S. dollars
Copaxone (Teva)	3,171
Tecfidera (Biogen)	3,118
Gilenya (Novartis	1,714
Avonex (Biogen)	1,685
Invega Sustenna (Janssen)	1,304
Latuda (Sunovion)	1,286
Tysabri (Biogen)	1,179
Rebif (Pfizer)	1,084
Aubagio (Sanofi)	923
Namenda XR (Allergan)	682
Seroquel XR (AstraZeneca)	633
Pristiq (Pfizer)	516
Ampyra (Acorda)	479
Abilify Maintena (Otsuka)	428
Betaseron (Bayer)	420
Risperdal Consta (J&J)	380
Abilify (Otsuka)	322
Plegridy (Biogen)	315
Trintellix (Takeda)	297
Wellbutrin XL (Valeant)	279

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

October 2016

More information

Region

United States

Survey time period

as of October 2016

Supplementary notes

* All values are projected. The original list inlcudes products FDA indicates as approved for treatimg MS, Parkinson's disease, Alzheimer's disease, depression, schizophrenia, bipolar and insomnia.

Open this statistic in...

Spanish

Citation formats